Piramal Pharma Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Piramal Pharma Limited Announces Results for Q2 and H1 FY26".
Press Release Nov 05 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Piramal Pharma
- Piramal Pharma Limited Announces Results for Q2 and H1 FY26
- Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
- Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
- Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)
- Piramal Pharma Publishes FY2025 Sustainability Report, Outlining Performance and Decarbonization Glidepath
Later from Piramal Pharma
- Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates
- Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities
- Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
- Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
- Piramal Pharma Limited Press Release Jan 29 2026
Follow Piramal Pharma into a list and get an email when it puts out news.
Follow Piramal Pharma